person · Reporting owner

Hussain Muhammad Raghib

Disclosed activity across 4 companies

Tapewire entity: 15106
SEC CIK: 0001680691

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CIRRUS LOGIC, INC.CRUS · Entity 3854	Director	July 29, 2026	July 31, 2026
Marvell Technology, Inc.MRVL · Entity 521	President, Products & Tech	April 15, 2025	April 18, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CIRRUS LOGIC, INC.

Report date July 29, 2026 · Filed July 31, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,579	Reported balance After 2026-07-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-07-29 · Grant · Acquired 1,998 · Balance 10,579 F1: Each restricted stock unit was the economic equivalent of one share of common stock. The restricted stock units vested on July 29, 2026. F2: Expiration Date of July 29, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-07-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-07-29 · Exercise / conversion · Disposed 1,998 · Balance 0 F1: Each restricted stock unit was the economic equivalent of one share of common stock. The restricted stock units vested on July 29, 2026. F2: Expiration Date of July 29, 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	1,623	Reported balance After 2026-07-31 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-07-31 · Grant · Acquired 1,623 · Balance 1,623 F3: Each restricted stock unit represents a contingent right to receive one share of Cirrus Logic common stock. F4: Restricted Stock Units granted upon re-election to Cirrus Logic, Inc.'s Board of Directors. F5: 100% of the restricted stock units will vest on the earlier of: (a) the date of the Company's next Annual Meeting or (b) on July 31, 2027, the 1-year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit was the economic equivalent of one share of common stock. The restricted stock units vested on July 29, 2026.

F2: Expiration Date of July 29, 2026.

F3: Each restricted stock unit represents a contingent right to receive one share of Cirrus Logic common stock.

F4: Restricted Stock Units granted upon re-election to Cirrus Logic, Inc.'s Board of Directors.

F5: 100% of the restricted stock units will vest on the earlier of: (a) the date of the Company's next Annual Meeting or (b) on July 31, 2027, the 1-year anniversary of the grant date.

Marvell Technology, Inc.

Report date April 15, 2025 · Filed April 18, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	722,889	Ending reported balance After 2025-04-15 transaction · row 8 8 source rows · reconciled sequence Row 1 · 2025-04-15 · Exercise / conversion · Acquired 3,171 · Balance 695,970 Row 2 · 2025-04-15 · Tax withholding · Disposed 1,573 · Balance 694,397 F1: Surrender of shares in payment of tax withholding due as a result of the vesting of restricted stock units ("RSUs"). Row 3 · 2025-04-15 · Exercise / conversion · Acquired 5,315 · Balance 699,712 Row 4 · 2025-04-15 · Tax withholding · Disposed 2,636 · Balance 697,076 F1: Surrender of shares in payment of tax withholding due as a result of the vesting of restricted stock units ("RSUs"). Row 5 · 2025-04-15 · Exercise / conversion · Acquired 3,252 · Balance 700,328 Row 6 · 2025-04-15 · Tax withholding · Disposed 1,613 · Balance 698,715 F1: Surrender of shares in payment of tax withholding due as a result of the vesting of restricted stock units ("RSUs"). Row 7 · 2025-04-15 · Exercise / conversion · Acquired 47,946 · Balance 746,661 Row 8 · 2025-04-15 · Tax withholding · Disposed 23,772 · Balance 722,889 F1: Surrender of shares in payment of tax withholding due as a result of the vesting of restricted stock units ("RSUs").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-15 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-04-15 · Exercise / conversion · Disposed 3,171 · Balance 0 F3: Each RSU represents a contingent right to receive one Marvell Technology, Inc. common share upon vesting. F4: This award fully vested on April 15, 2025.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	21,259	Reported balance After 2025-04-15 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2025-04-15 · Exercise / conversion · Disposed 5,315 · Balance 21,259 F3: Each RSU represents a contingent right to receive one Marvell Technology, Inc. common share upon vesting. F5: The remaining RSUs will vest on 07/15/2025, 10/15/2025, 01/15/2026 and 04/15/2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	26,017	Reported balance After 2025-04-15 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2025-04-15 · Exercise / conversion · Disposed 3,252 · Balance 26,017 F3: Each RSU represents a contingent right to receive one Marvell Technology, Inc. common share upon vesting. F6: The remaining RSUs will vest on 07/15/2025, 10/15/2025, 01/15/2026, 04/15/2026, 07/15/2026, 10/15/2026, 01/15/2027, and 04/15/2027.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-04-15 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2025-04-15 · Exercise / conversion · Disposed 47,946 · Balance 0 F3: Each RSU represents a contingent right to receive one Marvell Technology, Inc. common share upon vesting. F7: The grant is fully vested. Reflects the number of shares earned in respect of performance based restricted stock units granted on 04/15/2022. The achievement levels of the relative TSR performance metrics applicable to the award and the number of shares earned based on such results that were certified on 04/15/2025.
Common StockSEC Table I · non-derivative	IndirectBy Family Trusts	88,081	Reported balance Holding disclosure · report date 2025-04-15 · row 9 Holding and transaction disclosures are not merged. 1 source row Row 9 · Balance 88,081 F2: Held in trusts of which the Reporting Person is the trustee, for the benefit of members of his immediate family.

Filing footnotes · ownership attribution and instrument terms

F1: Surrender of shares in payment of tax withholding due as a result of the vesting of restricted stock units ("RSUs").

F2: Held in trusts of which the Reporting Person is the trustee, for the benefit of members of his immediate family.

F3: Each RSU represents a contingent right to receive one Marvell Technology, Inc. common share upon vesting.

F4: This award fully vested on April 15, 2025.

F5: The remaining RSUs will vest on 07/15/2025, 10/15/2025, 01/15/2026 and 04/15/2026.

F6: The remaining RSUs will vest on 07/15/2025, 10/15/2025, 01/15/2026, 04/15/2026, 07/15/2026, 10/15/2026, 01/15/2027, and 04/15/2027.

F7: The grant is fully vested. Reflects the number of shares earned in respect of performance based restricted stock units granted on 04/15/2022. The achievement levels of the relative TSR performance metrics applicable to the award and the number of shares earned based on such results that were certified on 04/15/2025.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CAVIUM, INC.

Report date July 06, 2018 · Filed July 06, 2018

Section 16 reporting ended · disclosed 2018-07-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	135,222	Reported balance After 2018-07-06 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2018-07-06 · Other · Disposed 228,698 · Balance 135,222 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018.
Common StockSEC Table I · non-derivative	Direct	15,543	Reported balance After 2018-07-06 transaction · row 3 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 3 · 2018-07-06 · Disposition to issuer · Disposed 83,679 · Balance 15,543 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018. F3: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F4: Disposed of pursuant to the Merger Agreement, whereby at the effective time of the Merger (the "Effective Time") each outstanding and unvested RSU was assumed and converted in the Merger into that number of Marvell restricted stock units of Marvell common stock, rounded down to the nearest whole share ("Converted RSUs"), equal to the product of (x) the number of shares of Company common stock subject to such RSU and (y) the Conversion Ratio (calculated to equal 4.0339). Any Converted RSU is subject to the same terms and conditions as were applicable under such RSU prior to the Effective Time.
Common StockSEC Table I · non-derivative	Direct	9,364	Reported balance After 2018-07-06 transaction · row 4 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 4 · 2018-07-06 · Disposition to issuer · Disposed 6,179 · Balance 9,364 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018. F5: Represents shares of common stock of the Company underlying performance-based restricted stock units ("PRSUs"). Until the Merger, the Reporting Person's right to this PRSU remained subject to the satisfaction of certain performance criteria. F6: Disposed of pursuant to the Merger Agreement, whereby at the Effective Time each outstanding and unvested PRSU was assumed and converted in the Merger into that number of Marvell restricted stock units of Marvell common stock, rounded down to the nearest whole share ("Converted PRSUs"), equal to the product of (x) the number of shares of Company common stock subject to such PRSU, assuming achievement of target-level performance with respect to each performance period, performance cycle or measurement cycle applicable to such PRSU and (y) the Conversion Ratio (calculated to equal 4.0339). Any Converted PRSU shall (A) vest based on the vesting date set forth in the award agreement applicable to such PRSU prior to the Effective Time, subject only to the continued service of the grantee with the Company, Marvell or any of their affiliates through the applicable vesting date, (B) not be subject to any performance based vesting terms following the Effective Time and (continued in footnote 7) F7: (C) otherwise be subject to the same terms and conditions as were applicable under such PRSU prior to the Effective Time.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2018-07-06 transaction · row 5 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 5 · 2018-07-06 · Disposition to issuer · Disposed 9,364 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018. F5: Represents shares of common stock of the Company underlying performance-based restricted stock units ("PRSUs"). Until the Merger, the Reporting Person's right to this PRSU remained subject to the satisfaction of certain performance criteria. F6: Disposed of pursuant to the Merger Agreement, whereby at the Effective Time each outstanding and unvested PRSU was assumed and converted in the Merger into that number of Marvell restricted stock units of Marvell common stock, rounded down to the nearest whole share ("Converted PRSUs"), equal to the product of (x) the number of shares of Company common stock subject to such PRSU, assuming achievement of target-level performance with respect to each performance period, performance cycle or measurement cycle applicable to such PRSU and (y) the Conversion Ratio (calculated to equal 4.0339). Any Converted PRSU shall (A) vest based on the vesting date set forth in the award agreement applicable to such PRSU prior to the Effective Time, subject only to the continued service of the grantee with the Company, Marvell or any of their affiliates through the applicable vesting date, (B) not be subject to any performance based vesting terms following the Effective Time and (continued in footnote 7) F7: (C) otherwise be subject to the same terms and conditions as were applicable under such PRSU prior to the Effective Time.
Common StockSEC Table I · non-derivative	IndirectSee footnote	99,222	Reported balance After 2018-07-06 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-07-06 · Disposition to issuer · Disposed 36,000 · Balance 99,222 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018. F2: Held in trusts of which the reporting person is the trustee, for the benefit of members of his immediate family.
Stock Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $37.63 · Expires 2020-03-22	Direct	0	Reported balance After 2018-07-06 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-07-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F8: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 9) F9: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339).
Stock Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $37.83 · Expires 2021-02-07	Direct	0	Reported balance After 2018-07-06 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-07-06 · Disposition to issuer · Disposed 25,000 · Balance 0 F8: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 9) F9: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339).
Stock Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $62.86 · Expires 2022-02-16	Direct	0	Reported balance After 2018-07-06 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-07-06 · Disposition to issuer · Disposed 12,886 · Balance 0 F8: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 9) F9: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339).
Stock Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $48.88 · Expires 2023-02-11	Direct	0	Reported balance After 2018-07-06 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-07-06 · Disposition to issuer · Disposed 36,181 · Balance 0 F8: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 9) F9: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339).
Stock Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $65.80 · Expires 2024-02-10	Direct	0	Reported balance After 2018-07-06 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2018-07-06 · Disposition to issuer · Disposed 28,762 · Balance 0 F8: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 9) F9: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of November 19, 2017 (the "Merger Agreement" and, the transaction contemplated therein, the "Merger"), by and among Cavium, Inc. (the "Company"), Marvell Technology Group Ltd. ("Marvell"), and Kauai Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Merger Sub"), whereby each share of Company common stock was canceled and automatically converted into $40.00 in cash, without interest, and 2.1757 shares of Marvell common stock (together, the "Per Share Amount"), with the fractional shares being paid in cash as provided in the Merger Agreement. The market value of the Per Share Amount is $86.43 per share, based on the trading price of Marvell common stock as of the end of trading on July 5, 2018.

F2: Held in trusts of which the reporting person is the trustee, for the benefit of members of his immediate family.

F3: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs").

F4: Disposed of pursuant to the Merger Agreement, whereby at the effective time of the Merger (the "Effective Time") each outstanding and unvested RSU was assumed and converted in the Merger into that number of Marvell restricted stock units of Marvell common stock, rounded down to the nearest whole share ("Converted RSUs"), equal to the product of (x) the number of shares of Company common stock subject to such RSU and (y) the Conversion Ratio (calculated to equal 4.0339). Any Converted RSU is subject to the same terms and conditions as were applicable under such RSU prior to the Effective Time.

F5: Represents shares of common stock of the Company underlying performance-based restricted stock units ("PRSUs"). Until the Merger, the Reporting Person's right to this PRSU remained subject to the satisfaction of certain performance criteria.

F6: Disposed of pursuant to the Merger Agreement, whereby at the Effective Time each outstanding and unvested PRSU was assumed and converted in the Merger into that number of Marvell restricted stock units of Marvell common stock, rounded down to the nearest whole share ("Converted PRSUs"), equal to the product of (x) the number of shares of Company common stock subject to such PRSU, assuming achievement of target-level performance with respect to each performance period, performance cycle or measurement cycle applicable to such PRSU and (y) the Conversion Ratio (calculated to equal 4.0339). Any Converted PRSU shall (A) vest based on the vesting date set forth in the award agreement applicable to such PRSU prior to the Effective Time, subject only to the continued service of the grantee with the Company, Marvell or any of their affiliates through the applicable vesting date, (B) not be subject to any performance based vesting terms following the Effective Time and (continued in footnote 7)

F7: (C) otherwise be subject to the same terms and conditions as were applicable under such PRSU prior to the Effective Time.

F8: Pursuant to the Merger Agreement, each outstanding Company stock option, other than Company stock options held by non-employee directors (other than directors who will serve on Marvell's board of directors following the Merger), whether vested or unvested, was assumed and converted into an option to purchase that number of shares of Marvell common stock (rounded down to the nearest whole share) equal the product of (x) the number of shares of Company common stock for which the Company stock option was exercisable multiplied by (y) the sum of (A) 2.1757 and the quotient obtained by dividing (i) $40.00 by (ii) the volume weighted average trading price of Marvell common stock on Nasdaq for the five (5) consecutive trading days ending on the trading day immediately preceding the closing date of the Merger (the sum, the "Conversion Ratio," (continued in footnote 9)

F9: calculated to equal 4.0339) at an exercise price per share (rounded up to the nearest whole cent) equal to the quotient obtained by dividing (1) the per share exercise price for the Company common stock for which the Company stock option was exercisable divided by (2) the Conversion Ratio (calculated to equal 4.0339).

MARVELL TECHNOLOGY GROUP LTD

Report date April 20, 2021 · Filed April 20, 2021

Section 16 reporting ended · disclosed 2021-04-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-04-20 transaction · row 1 1 source row Row 1 · 2021-04-20 · Disposition to issuer · Disposed 759,059 · Balance 0 F1: On April 20, 2021, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of October 29, 2020 (the "Merger Agreement"), by and among Marvell Technology Group Ltd. ("Marvell"), Marvell Technology, Inc. (f/k/a Maui HoldCo, Inc.), a wholly owned subsidiary of Marvell ("HoldCo"), Maui Acquisition Company Ltd, a wholly owned subsidiary of HoldCo ("Bermuda Merger Sub"), Indigo Acquisition Corp., a wholly owned subsidiary of HoldCo ("Delaware Merger Sub"), and Inphi Corporation ("Inphi"), Bermuda Merger Sub merged with and into Marvell with Marvell as the surviving corporation and a wholly owned subsidiary of Holdco (the "Bermuda Merger"), and Delaware Merger Sub merged with and into Inphi with Inphi as the surviving corporation and a wholly owned subsidiary of Holdco (the "Delaware Merger" and, together with the Bermuda Merger, the "Mergers"). F2: (Continued from footnote 1) At the effective time of the Bermuda Merger, each common share of Marvell, par value $0.002 per share ("Marvell Share"), was automatically converted into the right to receive one share of HoldCo common stock, par value $0.002 per share ("HoldCo Stock").
Common SharesSEC Table I · non-derivative	IndirectBy Family Trusts	Reported balance After 2021-04-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-04-20 · Disposition to issuer · Disposed 88,081 · Balance 0 F1: On April 20, 2021, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of October 29, 2020 (the "Merger Agreement"), by and among Marvell Technology Group Ltd. ("Marvell"), Marvell Technology, Inc. (f/k/a Maui HoldCo, Inc.), a wholly owned subsidiary of Marvell ("HoldCo"), Maui Acquisition Company Ltd, a wholly owned subsidiary of HoldCo ("Bermuda Merger Sub"), Indigo Acquisition Corp., a wholly owned subsidiary of HoldCo ("Delaware Merger Sub"), and Inphi Corporation ("Inphi"), Bermuda Merger Sub merged with and into Marvell with Marvell as the surviving corporation and a wholly owned subsidiary of Holdco (the "Bermuda Merger"), and Delaware Merger Sub merged with and into Inphi with Inphi as the surviving corporation and a wholly owned subsidiary of Holdco (the "Delaware Merger" and, together with the Bermuda Merger, the "Mergers"). F2: (Continued from footnote 1) At the effective time of the Bermuda Merger, each common share of Marvell, par value $0.002 per share ("Marvell Share"), was automatically converted into the right to receive one share of HoldCo common stock, par value $0.002 per share ("HoldCo Stock"). F3: Held in trusts of which the Reporting Person is the trustee, for the benefit of members of his immediate family.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-04-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-04-20 · Disposition to issuer · Disposed 35,540 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one Marvell Share upon vesting. At the effective time of the Bermuda Merger, each restricted stock unit related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a restricted stock unit relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting) that applied to such restricted stock unit immediately prior to the Mergers, except that, for the performance-based restricted stock units, the performance measures will relate to HoldCo instead of Marvell. F5: The restricted stock units vest on August 15, 2021.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-04-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-04-20 · Disposition to issuer · Disposed 16,269 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one Marvell Share upon vesting. At the effective time of the Bermuda Merger, each restricted stock unit related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a restricted stock unit relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting) that applied to such restricted stock unit immediately prior to the Mergers, except that, for the performance-based restricted stock units, the performance measures will relate to HoldCo instead of Marvell. F6: The restricted stock units vest on January 31, 2022.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-04-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-04-20 · Disposition to issuer · Disposed 27,415 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one Marvell Share upon vesting. At the effective time of the Bermuda Merger, each restricted stock unit related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a restricted stock unit relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting) that applied to such restricted stock unit immediately prior to the Mergers, except that, for the performance-based restricted stock units, the performance measures will relate to HoldCo instead of Marvell. F7: The restricted stock units vest on each of 7/15/2021, 10/15/2021, 1/15/2022 and 4/15/2022.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-04-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-04-20 · Disposition to issuer · Disposed 55,667 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one Marvell Share upon vesting. At the effective time of the Bermuda Merger, each restricted stock unit related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a restricted stock unit relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting) that applied to such restricted stock unit immediately prior to the Mergers, except that, for the performance-based restricted stock units, the performance measures will relate to HoldCo instead of Marvell. F8: The restricted stock units vest on each of 7/15/2021, 10/15/2021, 1/15/2022, 4/15/2022, 7/15/2022, 10/15/2022, 1/15/2023 and 4/15/2023.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-04-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-04-20 · Disposition to issuer · Disposed 39,668 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one Marvell Share upon vesting. At the effective time of the Bermuda Merger, each restricted stock unit related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a restricted stock unit relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting) that applied to such restricted stock unit immediately prior to the Mergers, except that, for the performance-based restricted stock units, the performance measures will relate to HoldCo instead of Marvell. F9: The restricted stock units vest on each of 7/15/2021, 10/15/2021, 1/15/2022, 4/15/2022, 7/15/2022, 10/15/2022, 1/15/2023, 4/15/2023, 7/15/2023, 10/15/2023, 1/15/2024, and 4/15/2024.
Performance Based Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-04-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-04-20 · Disposition to issuer · Disposed 399,644 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one Marvell Share upon vesting. At the effective time of the Bermuda Merger, each restricted stock unit related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a restricted stock unit relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting) that applied to such restricted stock unit immediately prior to the Mergers, except that, for the performance-based restricted stock units, the performance measures will relate to HoldCo instead of Marvell. F10: Value Creation Award that has been designed to provide a strong incentive to create a substantial increase in shareholder value. Vesting of these performance-based restricted stock units is dependent upon a significant increase in Marvell's stock price. The performance condition will be satisfied once Marvell's average stock price equals or exceeds $40.00 per share for 100 calendar days prior to the fourth anniversary of the date of grant ("Performance Condition"). The shares vest one year after the date the Performance Condition is satisfied. In the event of a change in control, the Performance Condition may be deemed partially satisfied depending on the value received in the transaction.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.33 · Expires 2020-03-22	Direct	Reported balance After 2021-04-20 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-04-20 · Disposition to issuer · Disposed 40,339 · Balance 0 F11: Each stock option related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a stock option relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting and exercise price) that applied to stock option immediately prior to the Mergers. F12: Stock option was fully vested and exercisable prior to the Mergers.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.38 · Expires 2021-02-07	Direct	Reported balance After 2021-04-20 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-04-20 · Disposition to issuer · Disposed 100,848 · Balance 0 F11: Each stock option related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a stock option relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting and exercise price) that applied to stock option immediately prior to the Mergers. F12: Stock option was fully vested and exercisable prior to the Mergers.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.58 · Expires 2022-02-16	Direct	Reported balance After 2021-04-20 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-04-20 · Disposition to issuer · Disposed 51,981 · Balance 0 F11: Each stock option related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a stock option relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting and exercise price) that applied to stock option immediately prior to the Mergers. F12: Stock option was fully vested and exercisable prior to the Mergers.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.12 · Expires 2023-02-11	Direct	Reported balance After 2021-04-20 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-04-20 · Disposition to issuer · Disposed 145,952 · Balance 0 F11: Each stock option related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a stock option relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting and exercise price) that applied to stock option immediately prior to the Mergers. F12: Stock option was fully vested and exercisable prior to the Mergers.
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.31 · Expires 2024-02-10	Direct	Reported balance After 2021-04-20 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2021-04-20 · Disposition to issuer · Disposed 116,024 · Balance 0 F11: Each stock option related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a stock option relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting and exercise price) that applied to stock option immediately prior to the Mergers. F12: Stock option was fully vested and exercisable prior to the Mergers.

Filing footnotes · ownership attribution and instrument terms

F1: On April 20, 2021, pursuant to the Agreement and Plan of Merger and Reorganization, dated as of October 29, 2020 (the "Merger Agreement"), by and among Marvell Technology Group Ltd. ("Marvell"), Marvell Technology, Inc. (f/k/a Maui HoldCo, Inc.), a wholly owned subsidiary of Marvell ("HoldCo"), Maui Acquisition Company Ltd, a wholly owned subsidiary of HoldCo ("Bermuda Merger Sub"), Indigo Acquisition Corp., a wholly owned subsidiary of HoldCo ("Delaware Merger Sub"), and Inphi Corporation ("Inphi"), Bermuda Merger Sub merged with and into Marvell with Marvell as the surviving corporation and a wholly owned subsidiary of Holdco (the "Bermuda Merger"), and Delaware Merger Sub merged with and into Inphi with Inphi as the surviving corporation and a wholly owned subsidiary of Holdco (the "Delaware Merger" and, together with the Bermuda Merger, the "Mergers").

F2: (Continued from footnote 1) At the effective time of the Bermuda Merger, each common share of Marvell, par value $0.002 per share ("Marvell Share"), was automatically converted into the right to receive one share of HoldCo common stock, par value $0.002 per share ("HoldCo Stock").

F3: Held in trusts of which the Reporting Person is the trustee, for the benefit of members of his immediate family.

F4: Each restricted stock unit represents a contingent right to receive one Marvell Share upon vesting. At the effective time of the Bermuda Merger, each restricted stock unit related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a restricted stock unit relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting) that applied to such restricted stock unit immediately prior to the Mergers, except that, for the performance-based restricted stock units, the performance measures will relate to HoldCo instead of Marvell.

F5: The restricted stock units vest on August 15, 2021.

F6: The restricted stock units vest on January 31, 2022.

F7: The restricted stock units vest on each of 7/15/2021, 10/15/2021, 1/15/2022 and 4/15/2022.

F8: The restricted stock units vest on each of 7/15/2021, 10/15/2021, 1/15/2022, 4/15/2022, 7/15/2022, 10/15/2022, 1/15/2023 and 4/15/2023.

F9: The restricted stock units vest on each of 7/15/2021, 10/15/2021, 1/15/2022, 4/15/2022, 7/15/2022, 10/15/2022, 1/15/2023, 4/15/2023, 7/15/2023, 10/15/2023, 1/15/2024, and 4/15/2024.

F10: Value Creation Award that has been designed to provide a strong incentive to create a substantial increase in shareholder value. Vesting of these performance-based restricted stock units is dependent upon a significant increase in Marvell's stock price. The performance condition will be satisfied once Marvell's average stock price equals or exceeds $40.00 per share for 100 calendar days prior to the fourth anniversary of the date of grant ("Performance Condition"). The shares vest one year after the date the Performance Condition is satisfied. In the event of a change in control, the Performance Condition may be deemed partially satisfied depending on the value received in the transaction.

F11: Each stock option related to a Marvell Share was assumed by HoldCo pursuant to the Merger Agreement and converted into a stock option relating to a share of HoldCo Stock, on the same terms and conditions as the original award (including with respect to vesting and exercise price) that applied to stock option immediately prior to the Mergers.

F12: Stock option was fully vested and exercisable prior to the Mergers.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 06, 2018 Filed Jul 12, 2018 17:42 UTC	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	116,024	Not disclosed Strike: $16.31	Not disclosed	Disclosure SEC source: 0001209191-18-042483 · doc4.xml · derivative · entry 7 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,024 Underlying: Common shares · 116,024 shares Expires 2024-02-10 F4 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. F7 · derivative.exercise_date: Exercisable in equal monthly installments on the 10th of each month beginning 7/10/2018 and ending 2/10/2021. Read SEC document
July 06, 2018 Filed Jul 12, 2018 17:42 UTC	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	145,952	Not disclosed Strike: $12.12	Not disclosed	Disclosure SEC source: 0001209191-18-042483 · doc4.xml · derivative · entry 6 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,952 Underlying: Common shares · 145,952 shares Expires 2023-02-11 F4 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. F6 · derivative.exercise_date: Exercisable in equal monthly installments on the 11th of each month beginning 7/11/2018 and ending 2/11/2020. Read SEC document
July 06, 2018 Filed Jul 12, 2018 17:42 UTC	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	51,981	Not disclosed Strike: $15.58	Not disclosed	Disclosure SEC source: 0001209191-18-042483 · doc4.xml · derivative · entry 5 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,981 Underlying: Common shares · 51,981 shares Expires 2022-02-16 F4 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. F5 · derivative.exercise_date: Exercisable in equal monthly installments on the 16th of each month beginning 7/16/18 and ending 2/16/2019. Read SEC document
July 06, 2018 Filed Jul 12, 2018 17:42 UTC	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	100,848	Not disclosed Strike: $9.38	Not disclosed	Disclosure SEC source: 0001209191-18-042483 · doc4.xml · derivative · entry 4 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,848 Underlying: Common shares · 100,848 shares Expires 2021-02-07 F4 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. Read SEC document
July 06, 2018 Filed Jul 12, 2018 17:42 UTC	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	40,339	Not disclosed Strike: $9.33	Not disclosed	Disclosure SEC source: 0001209191-18-042483 · doc4.xml · derivative · entry 3 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,339 Underlying: Common shares · 40,339 shares Expires 2020-03-22 F4 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. Read SEC document
July 06, 2018 Filed Jul 12, 2018 17:42 UTC	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantCommon shares	78,325	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-042483 · doc4.xml · nonDerivative · entry 2 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trusts Disclosed balance after: 575,903 F2 · shares: Received in exchange for 36,000 shares of Cavium, Inc. common stock in connection with the merger (the "Merger") of Cavium, Inc. into Marvell Technology Group Ltd. ("Marvell"). On the effective date of the Merger, the Reporting Person received the reported common shares of Marvell. F2 · price: Received in exchange for 36,000 shares of Cavium, Inc. common stock in connection with the merger (the "Merger") of Cavium, Inc. into Marvell Technology Group Ltd. ("Marvell"). On the effective date of the Merger, the Reporting Person received the reported common shares of Marvell. F3 · ownership.nature: Held in trusts of which the Reporting Person is the trustee, for the benefit of members of his immediate family. Read SEC document
July 06, 2018 Filed Jul 12, 2018 17:42 UTC	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantCommon shares	497,578	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-042483 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,578 F1 · shares: Received in exchange for 228,698 shares of Cavium, Inc. common stock in connection with the merger (the "Merger") of Cavium, Inc. into Marvell Technology Group Ltd. ("Marvell"). On the effective date of the Merger, the Reporting Person received the reported common shares of Marvell. F1 · price: Received in exchange for 228,698 shares of Cavium, Inc. common stock in connection with the merger (the "Merger") of Cavium, Inc. into Marvell Technology Group Ltd. ("Marvell"). On the effective date of the Merger, the Reporting Person received the reported common shares of Marvell. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantRestricted stock units · Derivative	65,076	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 13 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,075 Underlying: Common shares · 65,076 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one Marvell common share upon vesting. F21 · shares: Received in exchange for restricted stock units of Cavium, Inc. in connection with the Merger. On the effective date of the Merger the Reporting Person acquired 65,076 RSUs. F13 · price: Received in the Merger in exchange for restricted stock units of Cavium, Inc. F22 · derivative.exercise_date: This award vests as of 25% of the shares on each of January 31, 2019, 2020, 2021 and 2022. F22 · derivative.expiration_date: This award vests as of 25% of the shares on each of January 31, 2019, 2020, 2021 and 2022. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantRestricted stock units · Derivative	49,601	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 12 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,601 Underlying: Common shares · 49,601 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one Marvell common share upon vesting. F19 · shares: Received in exchange for restricted stock units of Cavium, Inc. in connection with the Merger. On the effective date of the Merger the Reporting Person acquired 49,601 RSUs. F13 · price: Received in the Merger in exchange for restricted stock units of Cavium, Inc. F20 · derivative.exercise_date: This award vests as to 1/3 of the shares on each of January 31, 2019, 2020 and 2021. F20 · derivative.expiration_date: This award vests as to 1/3 of the shares on each of January 31, 2019, 2020 and 2021. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantRestricted stock units · Derivative	41,106	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 11 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,105 Underlying: Common shares · 41,106 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one Marvell common share upon vesting. F18 · shares: Received in exchange for restricted stock units of Cavium, Inc. in connection with the Merger. On the effective date of the Merger the Reporting Person acquired 41,106 RSUs. F13 · price: Received in the Merger in exchange for restricted stock units of Cavium, Inc. F15 · derivative.exercise_date: This award vests as to 50% of the shares on each of January 31, 2019 and 2020. F15 · derivative.expiration_date: This award vests as to 50% of the shares on each of January 31, 2019 and 2020. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantRestricted stock units · Derivative	12,995	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 10 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,995 Underlying: Common shares · 12,995 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one Marvell common share upon vesting. F16 · shares: Received in exchange for restricted stock units of Cavium, Inc. in connection with the Merger. On the effective date of the Merger the Reporting Person acquired 12,995 RSUs. F13 · price: Received in the Merger in exchange for restricted stock units of Cavium, Inc. F17 · derivative.exercise_date: This award vests as to 100% of the shares on January 31, 2019. F17 · derivative.expiration_date: This award vests as to 100% of the shares on January 31, 2019. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantRestricted stock units · Derivative	18,887	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 9 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,886 Underlying: Common shares · 18,887 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one Marvell common share upon vesting. F14 · shares: Received in exchange for restricted stock units of Cavium, Inc. in connection with the Merger. On the effective date of the Merger the Reporting Person acquired 18,887 RSUs. F13 · price: Received in the Merger in exchange for restricted stock units of Cavium, Inc. F15 · derivative.exercise_date: This award vests as to 50% of the shares on each of January 31, 2019 and 2020. F15 · derivative.expiration_date: This award vests as to 50% of the shares on each of January 31, 2019 and 2020. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantRestricted stock units · Derivative	12,455	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 8 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,454 Underlying: Common shares · 12,455 shares Expires not disclosed F10 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one Marvell common share upon vesting. F11 · shares: Received in exchange for restricted stock units of Cavium, Inc. in connection with the Merger. On the effective date of the Merger the Reporting Person acquired 12,455 Restricted Stock Units "RSUs". F13 · price: Received in the Merger in exchange for restricted stock units of Cavium, Inc. F12 · derivative.exercise_date: This award vests as to 100% of the shares on January 31, 2019. F12 · derivative.expiration_date: This award vests as to 100% of the shares on January 31, 2019. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	116,024	Not disclosed Strike: $16.31	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 7 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,024 Underlying: Common shares · 116,024 shares Expires 2024-02-10 F6 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. F9 · derivative.exercise_date: 38,675 options shall become exercisable in equal monthly installments on the 10th of each month beginning 7/10/2018 and ending 2/10/2021. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	145,952	Not disclosed Strike: $12.12	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 6 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,952 Underlying: Common shares · 145,952 shares Expires 2023-02-11 F6 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. F8 · derivative.exercise_date: 30,407 options shall become exercisable in equal monthly installments on the 11th of each month beginning 7/11/2018 and ending 2/11/2020. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	51,981	Not disclosed Strike: $15.58	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 5 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,981 Underlying: Common shares · 51,981 shares Expires 2022-02-16 F6 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. F7 · derivative.exercise_date: 4,331 options shall become exercisable in equal monthly installments on the 16th of each month beginning 7/16/18 and ending 2/16/2019. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	100,848	Not disclosed Strike: $9.38	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 4 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,848 Underlying: Common shares · 100,848 shares Expires 2021-02-07 F6 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantStock option (right to buy) · Derivative	40,339	Not disclosed Strike: $9.33	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · derivative · entry 3 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,339 Underlying: Common shares · 40,339 shares Expires 2020-03-22 F6 · price: Received in the Merger in exchange for employee stock options to acquire shares of Cavium, Inc. stock. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantCommon shares	78,325	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · nonDerivative · entry 2 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trusts Disclosed balance after: 78,325 F4 · shares: Received in exchange for 36,000 shares of Cavium, Inc. common stock in connection with the Merger. On the effective date of the Merger, the Reporting Person received the reported common shares of Marvell. F4 · price: Received in exchange for 36,000 shares of Cavium, Inc. common stock in connection with the Merger. On the effective date of the Merger, the Reporting Person received the reported common shares of Marvell. F3 · balance_after: Correction to number of shares beneficially held directly and indirectly in Table I as reported. F5 · ownership.nature: Held in trusts of which the Reporting Person is the trustee, for the benefit of members of his immediate family. Read SEC document
July 06, 2018 Filed Nov 5, 2018 17:03 UTC Amendment	MARVELL TECHNOLOGY GROUP LTD MRVL · Entity 140170	GrantCommon shares	697,698	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-057230 · doc4a.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · EVP Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 697,698 F1 · shares: Received in exchange for 228,698 shares of Cavium, Inc. common stock in connection with the merger (the "Merger") of Cavium, Inc. into Marvell Technology Group Ltd. ("Marvell"). On the effective date of the Merger, the Reporting Person received the reported common shares of Marvell. F1 · price: Received in exchange for 228,698 shares of Cavium, Inc. common stock in connection with the merger (the "Merger") of Cavium, Inc. into Marvell Technology Group Ltd. ("Marvell"). On the effective date of the Merger, the Reporting Person received the reported common shares of Marvell. F2 · balance_after: Includes shares which were deemed to be beneficially held by the Reporting Person in connection with the Merger previously reported on Table II. F3 · balance_after: Correction to number of shares beneficially held directly and indirectly in Table I as reported. Read SEC document
February 16, 2018 Filed Feb 21, 2018 17:27 UTC	CAVIUM, INC. CAVM · Entity 165173	SaleCommon stock	20,000	$87.22	$1,744,400.00	Disclosure SEC source: 0001209191-18-012028 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 354,553 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. F2 · price: Shares were sold ranging from $86.63 per share to $87.61 per share. F3 · ownership.direct: Both direct and indirect. See footnote 4. F4 · ownership.nature: Of the amount of securities beneficially owned following reported transaction, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document
January 31, 2018 Filed Feb 1, 2018 17:22 UTC	CAVIUM, INC. CAVM · Entity 165173	GrantCommon stock	12,351	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-006527 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 374,553 F1 · kind: On February 10, 2017, pursuant to Cavium's 2016 Equity Incentive Plan, Cavium's Compensation Committee granted a one-year performance based RSU to the reporting person based on achievement of a certain milestone. The performance based RSU earned upon achievement of the certain milestone will vest and the underlying common stock of Cavium will be issued to the reporting person equally on January 31, 2018 and January 31, 2019. As determined by Cavium's Compensation Committee, the performance criteria was met at a level that caused 12,351 shares to be earned, and the reporting person received 6,175 shares of Cavium's common stock at no cost on January 31, 2018. The remaining 6,176 shares of Cavium's common stock will vest and delivered to the reporting person at no cost on January 31, 2019. F1 · price: On February 10, 2017, pursuant to Cavium's 2016 Equity Incentive Plan, Cavium's Compensation Committee granted a one-year performance based RSU to the reporting person based on achievement of a certain milestone. The performance based RSU earned upon achievement of the certain milestone will vest and the underlying common stock of Cavium will be issued to the reporting person equally on January 31, 2018 and January 31, 2019. As determined by Cavium's Compensation Committee, the performance criteria was met at a level that caused 12,351 shares to be earned, and the reporting person received 6,175 shares of Cavium's common stock at no cost on January 31, 2018. The remaining 6,176 shares of Cavium's common stock will vest and delivered to the reporting person at no cost on January 31, 2019. F2 · ownership.direct: Both direct and indirect. See footnote 3. F3 · ownership.nature: Of the amount of securities beneficially owned following reported transaction, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document
January 19, 2018 Filed Jan 22, 2018 18:22 UTC	CAVIUM, INC. CAVM · Entity 165173	GrantCommon stock	32,264	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-18-004793 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 362,202 F1 · kind: This is a Restricted Stock Unit (RSU) grant with a 4-year vesting term. The first 25% of this RSU grant will vest on January 31, 2019 and an additional 25% will vest thereafter on January 31st of each following year. On each vesting date, for each RSU vesting on such date, the reporting person will receive on share of Cavium's common stock at no cost. F1 · price: This is a Restricted Stock Unit (RSU) grant with a 4-year vesting term. The first 25% of this RSU grant will vest on January 31, 2019 and an additional 25% will vest thereafter on January 31st of each following year. On each vesting date, for each RSU vesting on such date, the reporting person will receive on share of Cavium's common stock at no cost. F2 · ownership.direct: Both direct and indirect holding. See footnote 3. F3 · ownership.nature: Of the amount of securities beneficially owned following reported transaction, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document
August 21, 2017 Filed Aug 21, 2017 20:40 UTC	CAVIUM, INC. CAVM · Entity 165173	Exercise / conversionStock option right to buy · Derivative	20,000	$0.00 Strike: $37.63	$0.00	Disclosure SEC source: 0001209191-17-049761 · doc4.xml · derivative · entry 3 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common stock · 20,000 shares Expires 2020-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/8th of the shares subject to the option vest on the six month anniversary of the vesting commencement date and 1/48th of the shares vest monthly thereafter over the next three and one half years. Read SEC document
August 21, 2017 Filed Aug 21, 2017 20:40 UTC	CAVIUM, INC. CAVM · Entity 165173	Exercise / conversionCommon stock	20,000	$37.63	$752,600.00	Disclosure SEC source: 0001209191-17-049761 · doc4.xml · nonDerivative · entry 2 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 329,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: Both direct and indirect holding. See footnote 4. F4 · ownership.nature: Of the amount of securities beneficially owned following reported transaction, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document
August 17, 2017 Filed Aug 21, 2017 20:40 UTC	CAVIUM, INC. CAVM · Entity 165173	SaleCommon stock	20,000	$61.85	$1,237,000.00	Disclosure SEC source: 0001209191-17-049761 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 309,938 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. F2 · price: Shares were sold ranging from $61.33 per share to $62.20 per share. F3 · ownership.direct: Both direct and indirect holding. See footnote 4. F4 · ownership.nature: Of the amount of securities beneficially owned following reported transaction, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document
February 17, 2017 Filed Feb 21, 2017 18:29 UTC	CAVIUM, INC. CAVM · Entity 165173	SaleCommon stock	90,000	$66.93	$6,023,700.00	Disclosure SEC source: 0001209191-17-012912 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 329,938 F1 · kind: The sale was made under a 10b5-1 trading plan as adopted by the reporting person. F2 · price: Shares were sold ranging from $66.10 per share to $67.20 per share. F3 · ownership.direct: Both direct and indirect holding. See footnote 4. F4 · ownership.nature: Of the amount of securities beneficially owned following reported transactions, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document
February 10, 2017 Filed Feb 13, 2017 19:12 UTC	CAVIUM, INC. CAVM · Entity 165173	GrantStock option right to buy · Derivative	28,762	$0.00 Strike: $65.80	$0.00	Disclosure SEC source: 0001209191-17-010213 · doc4.xml · derivative · entry 2 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,762 Underlying: Common stock · 28,762 shares Expires 2024-02-10 F4 · kind: This grant has a 4-year vesting term. 1/4 of the shares subject to the option vest on the first year anniversary of the grant date and the remaining shares will vest monthly thereafter over the next three years. F4 · derivative.exercise_date: This grant has a 4-year vesting term. 1/4 of the shares subject to the option vest on the first year anniversary of the grant date and the remaining shares will vest monthly thereafter over the next three years. Read SEC document
February 10, 2017 Filed Feb 13, 2017 19:12 UTC	CAVIUM, INC. CAVM · Entity 165173	GrantCommon stock	32,789	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-010213 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 419,938 F1 · kind: This is a Restricted Stock Unit (RSU) grant with a 4-year vesting term. The first 25% of this RSU grant will vest on January 31, 2018; and an additional 25% will vest thereafter on January 31st of each following year. On each vesting date, for each RSU vesting on such date, the reporting person will receive one share of Cavium's common stock at no cost. F1 · price: This is a Restricted Stock Unit (RSU) grant with a 4-year vesting term. The first 25% of this RSU grant will vest on January 31, 2018; and an additional 25% will vest thereafter on January 31st of each following year. On each vesting date, for each RSU vesting on such date, the reporting person will receive one share of Cavium's common stock at no cost. F2 · ownership.direct: Both direct and indirect. See footnote 3. F3 · ownership.nature: Of the amount of securities beneficially owned following reported transactions, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document
January 31, 2017 Filed Feb 2, 2017 19:19 UTC	CAVIUM, INC. CAVM · Entity 165173	GrantCommon stock	21,739	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-17-007318 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 387,149 F1 · kind: On February 11, 2016, pursuant to Cavium's 2007 Equity Incentive Plan, Cavium's Compensation Committee granted a one-year performance based RSU to the reporting person based on achievement of a certain milestone. The performance based RSU earned upon achievement of the certain milestone will vest and the underlying common stock of Cavium will be issued to the reporting person on January 31, 2017. As determined by Cavium's Compensation Committee on January 27, 2017, the performance criteria was met at a level that caused 21,739 shares to vest, and the reporting person received the same number of shares of Cavium's common stock at no cost. F1 · price: On February 11, 2016, pursuant to Cavium's 2007 Equity Incentive Plan, Cavium's Compensation Committee granted a one-year performance based RSU to the reporting person based on achievement of a certain milestone. The performance based RSU earned upon achievement of the certain milestone will vest and the underlying common stock of Cavium will be issued to the reporting person on January 31, 2017. As determined by Cavium's Compensation Committee on January 27, 2017, the performance criteria was met at a level that caused 21,739 shares to vest, and the reporting person received the same number of shares of Cavium's common stock at no cost. F2 · ownership.direct: Both direct and indirect holding. See footnote 3. F3 · ownership.nature: Of the amount of securities beneficially owned following reported transactions, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document
January 04, 2017 Filed Jan 6, 2017 18:08 UTC	CAVIUM, INC. CAVM · Entity 165173	Exercise / conversionStock option right to buy · Derivative	37,500	$0.00 Strike: $24.16	$0.00	Disclosure SEC source: 0001209191-17-002755 · doc4.xml · derivative · entry 2 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 37,500 shares Expires 2017-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/8th of the shares subject to the option vest on the six month anniversary of the vesting commencement date and 1/48th of the shares vest monthly thereafter over the next three and one half years. Read SEC document
January 04, 2017 Filed Jan 6, 2017 18:08 UTC	CAVIUM, INC. CAVM · Entity 165173	Exercise / conversionCommon stock	37,500	$24.16	$906,000.00	Disclosure SEC source: 0001209191-17-002755 · doc4.xml · nonDerivative · entry 1 Hussain Muhammad Raghib · CIK 0001680691 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 365,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Both direct and indirect holding. See footnote 2. F2 · ownership.nature: Of the amount of securities beneficially owned following reported transactions, 36,000 shares are owned indirectly by the reporting person through multiple family trusts. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.